Optimal dose finding for novel antimalarial combination therapy

Tropical Medicine and International Health

Volumn 17, Issue 4, 2012, Pages 409-413

  Duparc, S ^a   Lanza, C ^a   Ubben, D ^a   Borghini Fuhrer, I ^a   Kellam, L ^b  

^a Medicines for Malaria Venture   (Switzerland)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antimalarial; Drug development; Factorial design

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMALARIAL AGENT; ARTEMISININ;

ANTIMALARIAL AGENT; DISEASE TREATMENT; DRUG DEVELOPMENT; MALARIA; MEDICINE; OPTIMIZATION; PARASITE RESISTANCE;

ARTICLE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; MALARIA; MONOTHERAPY; PHARMACODYNAMICS; PLASMODIUM VIVAX; TREATMENT OUTCOME;

ANTIMALARIALS; ARTEMISININS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA; MODELS, STATISTICAL; PLASMODIUM; QUININE;

EID: 84859002052     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2012.02963.x     Document Type: Article

References (23)

1. Alin MH, Ashton M, Kihamia CM, et al. (1996) Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. British Journal of Clinical Pharmacology 41, 587-592.
2. Apt A & Kramnik I (2009) Man and mouse TB: contradictions and solutions. Tuberculosis (Edinb) 89, 195-198.
3. Arnold L, Tyagi RK, Meija P, et al. (2011) Further improvements of the P. falciparum humanized mouse model. PLoS One 6, e18045.
4. Baird JK (2011) Resistance to chloroquine unhinges vivax malaria therapeutics. Antimicrobial Agents and Chemotherapy 55, 1827-1830.
5. Bell A (2005) Antimalarial drug synergism and antagonism: mechanistic and clinical significance. FEMS Microbiology Letters 253, 171-184.
6. Carneiro I, Roca-Feltrer A, Griffin JT, et al. (2010) Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis. PLoS One 5, e8988.
7. Co EM, Dennull RA, Reinbold DD, et al. (2009) Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay. Antimicrobial Agents and Chemotherapy 53, 2557-2563.
8. Galappaththy GN, Omari AA & Tharyan P (2007) Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database of Systematic Reviews (1), CD004389.
9. Giao PT, Binh TQ, Kager PA, et al. (2001) Artemisinin for treatment of uncomplicated falciparum malaria: is there a place for monotherapy? The American Journal of Tropical Medicine and Hygiene 65, 690-695.
10. Langhorne J, Buffet P, Galinski M, et al. (2011) The relevance of non-human primate and rodent malaria models for humans. Malaria Journal 10, 23.
11. Mulenga M, Malunga P, Bennett S, et al. (2006) Folic acid treatment of Zambian children with moderate to severe malaria anemia. The American Journal of Tropical Medicine and Hygiene 74, 986-990.
12. Myers R, Montgomery D & Anderson-Cook C (2009) Response Surface Methodology: Process and Product Optimization Using Designed Experiments. John Wiley & Sons, Hoboken, NJ.
13. Noedl H, Wongsrichanalai C & Wernsdorfer WH (2003) Malaria drug-sensitivity testing: new assays, new perspectives. Trends in Parasitology 19, 175-181.
14. Noedl H, Se Y, Schaecher K, et al. (2008) Evidence of artemisinin-resistant malaria in western Cambodia. The New England Journal of Medicine 359, 2619-2620.
15. Pool JL, Cushman WC, Saini RK, et al. (1997) Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. American Journal of Hypertension 10, 117-123.
16. Roll Back Malaria (2001) The Use of Antimalarial Drugs: Report of an Informal Consultation. World Health Organization, Geneva. Accessed 8/4/2011.
17. The malERA Consultative Group on Drugs (2011) A research agenda for malaria eradication: drugs. PLoS Med 8, e1000402.
18. Wein S, Maynadier M, Tran Van Ba C, et al. (2010) Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. Journal of Clinical Microbiology 48, 1651-1660.
19. White NJ (2010) Artemisinin resistance - the clock is ticking. Lancet 376, 2051-2052.
20. Wootton DG, Opara H, Biagini GA, et al. (2008) Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap™) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria. PLoS One 3, e1779.
21. World Health Organization (2010) Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000-2010. World Health Organization, Geneva. Accessed 20/3/2011.
22. World Health Organization (2011) Global Plan for Artemisinin Resistance Containment (GPARC). World Health Organization, Geneva. Accessed 20/3/2011.
23. Zhuang DM & Li JY (2011) A few specialized issues that should be focused on anti-HIV drug evaluation in vitro. Virologica Sinica 25, 301-306.